4-phenoxythieno[2,3-c]pyridine-2-carboxylic acid | 1009104-22-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-phenoxythieno[2,3-c]pyridine-2-carboxylic acid
• 英文别名: 4-Phenoxy-thieno[2,3-c]pyridine-2-carboxylic acid
• CAS: 1009104-22-6
• 化学式: C₁₄H₉NO₃S
• 分子量: 271.296
• InChiKey: XSFXGESBIUOEFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-phenoxythieno[2,3-c]pyridine-2-carboxylic acid 以 二苯醚 为溶剂， 反应 20.0h， 以84%的产率得到4-phenoxythieno[2,3-c]pyridine
  参考文献：
  名称：

  A facile and general synthesis of 2,4‐Di‐ and 2,4,7‐trisubstituted thieno[2,3‐c]pyridines

  摘要：

  Abstractmagnified imageTreatment of 3,5‐dibromo‐ or 3,5‐dichloro‐pyridine‐4‐carboxaldehyde 2 with one equivalent of methyl thioglycolate, followed by exposure to base, provided 4‐bromo‐ or 4‐chloro‐thieno[2,3‐c]pyridine‐2‐carboxylate 4 in good yields. Oxidation of the thieno[2,3‐c]pyridine scaffold such as 7 with mCPBA, followed by treatment with POBr3, introduced a bromine exclusively at the 7‐position of the heterocycle. The 4‐ or 7‐bromide of the thienopyridines readily underwent Suzuki, Stille coupling, and Buchwald amination reactions, to afford 4‐ or 7‐substituted analogs 6 or 11. The 2‐carboxylate of 4b or 12 was smoothly removed through saponification and decarboxylation to furnish 15 or 16. Deprotonation of the thienopyridine at C‐2 position, followed by trapping with trimethyltin chloride, afforded a 2‐stannyl analog, which was readily converted to other C‐2 derivatives via Stille reaction.

  DOI：

  10.1002/jhet.5570450106
• 作为产物：
  描述：

  methyl 4-phenoxythieno[2,3-c]pyridine-2-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 4-phenoxythieno[2,3-c]pyridine-2-carboxylic acid
  参考文献：
  名称：

  Selective Inhibition of ICAM-1 and E-Selectin Expression in Human Endothelial Cells. 2. Aryl Modifications of 4-(Aryloxy)thieno[2,3-c]pyridines with Fine-Tuning at C-2 Carbamides

  摘要：

  The elevated expression of cell adhesion molecules (CAMs) on the lumenal surface of vascular endothelial cells is a critical early event in the complex inflammatory process. The adhesive interactions of these CAMs that include E-selectin, ICAM-1, and VCAM-1 with their counterreceptors on leukocytes, such as integrins of the alpha (L)beta (2) family, result in migration of the leukocytes to the site of inflammation and cause tissue injury. Pharmaceutical agents that could suppress the induced expression of one or more of these cell adhesion molecules would provide a novel mechanism to attenuate the inflammatory responses associated with chronic inflammatory diseases. A-205804 (1), a potent and selective inhibitor of the induced expression of E-selectin and ICAM-1 over VCAM-1, was further modified with emphasis at the C-4 and C-2 positions to identify a more potent drug candidate with a good pharmacokinetic profile and physical properties. Replacement of the C-4 sulfur linkage in I with an oxygen atom eliminated one of the two major metabolites for this lead molecule. The para-position of the 4-phenoxy group of the thieno[2,3-c]pyridine lead is found to be very critical for a higher in vitro potency and selectivity of E-selectin and ICAM-1 over VCAM-1 expression. This position is presumably close to the solvent-accessible region of the target protein-inhibitor complex. An attempt to install a water-solubilizing group at the para-position of the phenoxy group to increase the aqueous solubility of this lead series through various linkages failed to provide an ideal inhibitor. Only small substituents such as fluorine are tolerated at the meta- and ortho-positions of the 4-phenoxy to retain a good in vitro potency. Bromo, trifluoromethyl, pyrazol-1-yl, and imidazol-1-yl are among the better substituents at the para-position. With fine-tuning at the C-2 position we discovered a series of very potent (IC50 < 5 nM for ICAM-1) and selective (> 200-fold vs VCAM-1) inhibitors with a good pharmacokinetic profile. Demonstrated efficacy in a rat rheumatoid arthritis model and in a mice asthma model with selected compounds is also reported.

  DOI：

  10.1021/jm0101702

文献信息

• Kinase inhibitors as therapeutic agents
  申请人：Cusack Kevin

  公开号：US20060074102A1

  公开（公告）日：2006-04-06

  A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

  式(I)化合物或其药学上可接受的盐，其中取代基如本文所定义，可用作激酶抑制剂。
• KINASE INHIBITORS AS THERAPEUTIC AGENTS
  申请人：ABBOTT LABORATORIES

  公开号：EP1753428A2

  公开（公告）日：2007-02-21
• [EN] KINASE INHIBITORS AS THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS DE KINASES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：ABBOTT LAB

  公开号：WO2005110410A2

  公开（公告）日：2005-11-24

  A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.